RPG Life Sciences' Q3 FY 2025-26 Quarterly Results
- 28 Jan 2026
Result Summary
- RPG Life Sciences Ltd reported a 1.5% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 4.2%.
- Its expenses for the quarter were down by 1.4% QoQ and up 13.0% YoY.
- The net profit decreased 39.9% QoQ and decreased 36.6% YoY.
- The earnings per share (EPS) of RPG Life Sciences Ltd stood at 13.38 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 183.44 | 186.22 | 176.02 | -1.5% | 4.2% |
Total Expenses | 145.90 | 147.99 | 129.13 | -1.4% | 13.0% |
Profit Before Tax | 29.12 | 49.45 | 46.89 | -41.1% | -37.9% |
Tax | 6.99 | 12.60 | 11.96 | -44.5% | -41.6% |
Profit After Tax | 22.13 | 36.85 | 34.93 | -39.9% | -36.6% |
Earnings Per Share | 13.38 | 22.28 | 21.12 | -39.9% | -36.6% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
RPG Life Sciences Ltd is a prominent player in the pharmaceutical industry, known for its diverse range of products and services. The company is engaged primarily in the manufacturing and marketing of pharmaceutical products, including active pharmaceutical ingredients (APIs), formulations, and biotechnology products. The company operates within the healthcare sector, serving both domestic and international markets. Recent major developments for RPG Life Sciences Ltd are not available in the provided data, and thus, any further specifics on strategic changes or new product launches remain unspecified based on the current information.
Revenue
During Q3FY26, RPG Life Sciences Ltd reported a total income of ₹183.44 crores, reflecting a slight decrease of 1.5% from ₹186.22 crores in Q2FY26. However, when compared to Q3FY25, the total income showed a year-over-year increase of 4.2% from ₹176.02 crores. The revenue trends indicate variability in the company's income flow on a quarterly basis, with a moderate year-on-year growth which suggests a degree of stability in its revenue generation capabilities over the longer term.
Profitability
In the third quarter of the fiscal year 2026, RPG Life Sciences Ltd recorded a profit before tax of ₹29.12 crores, which marked a significant decrease of 41.1% compared to the previous quarter's ₹49.45 crores. On a year-over-year basis, this figure also represents a decline of 37.9% from ₹46.89 crores in Q3FY25. The profit after tax for Q3FY26 stood at ₹22.13 crores, down 39.9% from ₹36.85 crores in Q2FY26 and 36.6% lower than the ₹34.93 crores achieved in Q3FY25. These figures highlight a notable reduction in profitability both quarter-over-quarter and year-over-year. The earnings per share followed a similar trend, decreasing to ₹13.38 in Q3FY26 from ₹22.28 in Q2FY26 and ₹21.12 in Q3FY25.
Operating Metrics
Total expenses for RPG Life Sciences Ltd in Q3FY26 were ₹145.90 crores, showing a marginal decrease of 1.4% from ₹147.99 crores in Q2FY26. Compared to the same quarter in the previous fiscal year, there was a 13.0% increase from ₹129.13 crores. The tax expenses for Q3FY26 totaled ₹6.99 crores, representing a 44.5% decrease from ₹12.60 crores in Q2FY26, and a 41.6% decrease from ₹11.96 crores in Q3FY25. These operating metrics provide insights into the company's cost management and tax liabilities during the period, highlighting substantial reductions in tax expenses both quarterly and annually, amidst rising operational costs year-over-year.